The Food and Drug Administration on April 1 approved Eli Lilly's new weight-loss pill, giving consumers a second option in the growing non-injectable GLP-1 weight-loss drug market.
Lilly said it will sell its weight-loss pill under the brand name Foundayo. The FDA approved the once-daily prescription pill for adults who have obesity or are overweight with weight-related medical problems.
The emergence of Foundayo gives consumers another GLP-1 weight-loss pill option. Novo Nordisk's Wegovy had been the only FDA-approved GLP-1 pill available since December 2025.
Both Lilly and Novo Nordisk are betting daily weight-loss pills will be a popular option for consumers who want to avoid a shot. Lilly's Zepbound and Novo's Wegovy are injectable weight-loss drugs that have driven demand for weight-loss medications.
Consumers whose insurance doesn't cover weight-loss medications can purchase Foundayo at $149 for a one-month supply of the lowest dose and up to $349 for additional monthly doses. Higher dosages begin at $299 for a one‑month prescription under the Foundayo's self-pay program.
